Gilead Sciences Inc
NASDAQ:GILD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
62.79
97.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GILD stock under the Base Case scenario is 89.71 USD. Compared to the current market price of 89.76 USD, Gilead Sciences Inc is Fairly Valued.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Gilead Sciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GILD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, an...
Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, and cardiovascular conditions, positioning itself as a leader in addressing some of the world's most pressing health challenges.
For investors, Gilead Sciences represents a compelling opportunity amid a rapidly evolving pharmaceutical market. The company’s robust pipeline of candidates and ongoing research into novel therapeutic areas suggest potential for sustained growth and profitability. With a strong commitment to innovation, Gilead is not only focused on maximizing the utility of its existing treatments but is also exploring partnerships and acquisitions to bolster its drug development capabilities. As the global demand for effective treatments rises, Gilead stands to benefit from its established reputation, financial resilience, and strategic investments, making it a noteworthy consideration for those looking to invest in a company that is dedicated to improving health outcomes worldwide.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines, primarily in the fields of antiviral drugs, HIV/AIDS, liver diseases, cancer, inflammation, and respiratory diseases. Here are the core business segments of Gilead Sciences:
-
Antiviral Therapies:
- This segment includes treatments for HIV/AIDS, Hepatitis B, Hepatitis C, and influenza. Gilead is well-known for its antiretroviral therapies that provide viral load control and improve the quality of life for HIV patients.
- Notable products include Truvada, Descovy, Biktarvy, and Harvoni.
-
Liver Disease:
- Gilead has developed treatments for chronic hepatitis B and hepatitis C. The company gained significant recognition with its Hepatitis C treatments, which have revolutionized the disease's management.
- Key products include Sovaldi and Epclusa.
-
Oncology:
- In recent years, Gilead has expanded into oncology, focusing on innovative treatments for various cancers.
- The company’s research includes targeted therapies, immunotherapy, and CAR T-cell therapy, with products such as Yescarta for certain types of blood cancer.
-
Inflammation Diseases:
- This segment focuses on treatments for autoimmune diseases and other inflammatory conditions. The company has developed therapies aimed at addressing various chronic inflammatory disorders.
-
Respiratory Diseases:
- Gilead has also looked to develop therapeutics for respiratory diseases, including opportunities related to COVID-19. For example, Remdesivir (Veklury) has been a pivotal treatment in the management of severe cases of the virus.
-
Research and Development:
- A significant part of Gilead's strategy is heavily investing in R&D to explore new drug candidates and improve existing therapies. The company is involved in developing therapies in various therapeutic areas, including novel approaches to treat diseases with high unmet medical needs.
-
Collaboration and Partnerships:
- Gilead engages in collaborations with other pharmaceutical companies and biotech firms as part of its strategy to enhance its pipeline, expand its therapy offerings, and leverage technological advancements.
Overall, Gilead Sciences is recognized for its robust portfolio in antiviral therapies and its evolving presence in oncology and other therapeutic areas, positioning the company to address both current and emerging healthcare challenges.
Gilead Sciences Inc. possesses several unique competitive advantages that bolster its position in the biopharmaceutical industry:
-
Strong Pipeline of Antiviral Therapies: Gilead has established a reputation for developing groundbreaking antiviral medications, particularly in the areas of HIV, hepatitis B, hepatitis C, and influenza. Its existing portfolio includes leading drugs like Biktarvy and Truvada, which provides a competitive edge due to strong demand and brand recognition.
-
Expertise in Research and Development: Gilead invests heavily in R&D, leading to innovative therapies that often address unmet medical needs. This commitment allows Gilead to stay ahead of competitors by developing first-in-class or best-in-class treatments.
-
Regulatory and Commercialization Expertise: Gilead has demonstrated success in navigating complex regulatory landscapes and efficiently bringing products to market. Their experience in securing approvals from the U.S. FDA and other global regulatory bodies is a significant advantage.
-
Strong Intellectual Property Portfolio: Gilead has a robust patent portfolio that protects its key therapies, giving it considerable time to recoup R&D investments without the threat of generic competition. This exclusivity can lead to substantial revenue generation.
-
Established Relationships with Healthcare Providers: Gilead’s long-standing relationships with healthcare providers and payers enhance its market presence and accessibility of its therapies, further solidifying its competitive position.
-
Global Reach and Market Penetration: Gilead has a strong global footprint, allowing it to access diverse markets. Its ability to adapt products and marketing strategies to various regions enhances its competitiveness on a global scale.
-
Focus on Specialty Medicines: Gilead’s concentration on specialty drugs, particularly in the antiviral and oncology spaces, allows for high margins and dedicated patient populations, which are less susceptible to erosion from low-cost alternatives.
-
Strategic Partnerships and Acquisitions: Gilead has historically engaged in strategic partnerships and acquisitions that complement its existing portfolio and enhance its research capabilities. This proactive approach to growth can accelerate innovation and market penetration.
-
Data Analytics and Innovation in Patient Care: Gilead leverages data analytics to improve patient outcomes and streamline its drug development processes. By focusing on real-world evidence, Gilead can refine its therapies based on actual patient data, enhancing the effectiveness of its treatments.
-
Commitment to Access and Affordability: Gilead has initiatives aimed at improving access to its medications in various markets, including pricing strategies and patient assistance programs. This commitment can enhance its reputation and foster loyalty among healthcare providers and patients.
These unique competitive advantages allow Gilead Sciences Inc to maintain a robust position in the biopharmaceutical industry, effectively positioning itself against its rivals.
Gilead Sciences Inc. faces several risks and challenges in the near future, including:
-
Regulatory Risks: Changes in regulations, approvals, or policies from health authorities can impact Gilead's ability to launch new products or maintain its existing market position.
-
Competition: The biopharmaceutical industry is highly competitive. Gilead faces competition from other biotech and pharmaceutical companies, particularly in its key therapeutic areas such as HIV, hepatitis, and oncology.
-
Patent Expiry: The expiration of key patents can lead to increased competition from generic products, which may significantly affect Gilead's revenue from certain drugs.
-
Pipeline Development: Gilead relies on its pipeline of new drugs to drive future growth. Delays in clinical trials or failures in the development process can hinder progress and financial performance.
-
Market Dynamics: Changes in market dynamics, such as pricing pressures from payers or shifts in treatment paradigms, can negatively impact sales of Gilead’s products.
-
Global Health Crises: Events like pandemics can disrupt supply chains and impact healthcare budgets, affecting sales and operations for the company.
-
Reputation and Public Perception: Issues related to pricing, access to medicines, or corporate governance can hurt Gilead's reputation, potentially affecting sales and partnerships.
-
Technological Changes: Rapid advancements in biotechnology and different therapeutic approaches may require Gilead to continuously innovate to stay competitive.
-
Economic Conditions: Global economic downturns can influence healthcare spending and affect the overall demand for Gilead’s products.
-
Investor Expectations: Expectations for growth and profitability can lead to significant stock volatility if Gilead fails to meet these expectations.
In navigating these challenges, Gilead will need to leverage its innovative capabilities, maintain robust research and development efforts, and engage in strategic collaborations to sustain its market position.
Revenue & Expenses Breakdown
Gilead Sciences Inc
Balance Sheet Decomposition
Gilead Sciences Inc
Current Assets | 13.1B |
Cash & Short-Term Investments | 5B |
Receivables | 4.6B |
Other Current Assets | 3.4B |
Non-Current Assets | 41.5B |
PP&E | 5.4B |
Intangibles | 28.9B |
Other Non-Current Assets | 7.2B |
Current Liabilities | 11.7B |
Other Current Liabilities | 11.7B |
Non-Current Liabilities | 24.4B |
Other Non-Current Liabilities | 24.4B |
Earnings Waterfall
Gilead Sciences Inc
Revenue
|
28.3B
USD
|
Cost of Revenue
|
-6.3B
USD
|
Gross Profit
|
22B
USD
|
Operating Expenses
|
-11.2B
USD
|
Operating Income
|
10.9B
USD
|
Other Expenses
|
-10.7B
USD
|
Net Income
|
126m
USD
|
Free Cash Flow Analysis
Gilead Sciences Inc
USD | |
Free Cash Flow | USD |
Gilead Sciences reported a robust third quarter in 2024, achieving total product sales of $7.5 billion, a 7% year-over-year increase, driven by growth in HIV, oncology, and liver disease. The company raised its revenue guidance for 2024, predicting total product sales between $27.8 billion and $28.1 billion. HIV sales grew 9% to $5.1 billion, surpassing previous growth expectations. Notably, lenacapavir for HIV prevention has been awarded breakthrough therapy designation and is set for regulatory filing by year-end. Livdelzi's launch exceeded expectations, and Gilead anticipates substantial momentum into 2025. Earnings per share guidance has been increased to $4.25-$4.45.
What is Earnings Call?
GILD Profitability Score
Profitability Due Diligence
Gilead Sciences Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Gilead Sciences Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
GILD Solvency Score
Solvency Due Diligence
Gilead Sciences Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Gilead Sciences Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GILD Price Targets Summary
Gilead Sciences Inc
According to Wall Street analysts, the average 1-year price target for GILD is 97.82 USD with a low forecast of 69.69 USD and a high forecast of 131.25 USD.
Dividends
Current shareholder yield for GILD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
GILD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The company sells and distributes its products in the United States through the wholesale channel. The company operates in more than 35 countries worldwide.
Contact
IPO
Employees
Officers
The intrinsic value of one GILD stock under the Base Case scenario is 89.71 USD.
Compared to the current market price of 89.76 USD, Gilead Sciences Inc is Fairly Valued.